FIGS, Inc. experienced a significant intraday surge, with its stock price soaring 21.53% during Friday's trading session.
The sharp upward movement was driven by the company's release of its fourth quarter and full year 2025 financial results, which significantly exceeded analyst expectations. FIGS reported Q4 net revenues of $201.9 million, a 33% year-over-year increase that handily beat the consensus estimate. The company's diluted earnings per share also crushed analyst forecasts.
Furthermore, the healthcare apparel brand provided an optimistic outlook for fiscal year 2026, forecasting net revenue growth of 10% to 12%. The strong performance was complemented by positive analyst actions, including KeyBanc upgrading the stock to Overweight from Sector Weight with a $17 price target, and Roth Capital raising its price target to $15.50 from $12.
Comments